By modulating immune checkpoint pathways, such as the CD47-SIRPα axis, PCEs reprogram immunosuppressive tumor-associated macrophages (TAMs) into pro-inflammatory M1 phenotypes, promoting phagocytosis and antigen presentation [4,14,22,74,76,83]. The gene discussed is SIRPA; the disease is neoplasm.